NASDAQ:CLBS - Caladrius Biosciences Stock Price, Price Target & More

$4.63 +0.11 (+2.43 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$4.63
Today's Range$4.57 - $4.68
52-Week Range$2.63 - $6.35
Volume11,789 shs
Average Volume31,883 shs
Market Capitalization$43.18 million
P/E Ratio-2.60
Dividend YieldN/A
Beta1.17

About Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences logoCaladrius Biosciences, Inc. is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company's lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient's own numerically and functionally enhanced Tregs. This therapy is based on a platform technology for immunomodulation. The Company is focused on commencing The Sanford Project: T-Rex Study, a Phase II prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate its Treg product candidate, CLBS03, in adolescents with recent onset T1D. The Company plans to develop its product candidate, CLBS12, in Japan, which is an autologous therapy that derives its cells from peripheral blood through apheresis.

Receive CLBS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLBS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLBS
CUSIPN/A
Phone908-842-0100

Debt

Debt-to-Equity RatioN/A
Current Ratio6.56%
Quick Ratio6.56%

Price-To-Earnings

Trailing P/E Ratio-2.60
Forward P/E Ratio-1.52
P/E GrowthN/A

Sales & Book Value

Annual Sales$35.28 million
Price / Sales1.25
Cash FlowN/A
Price / CashN/A
Book Value$5.30 per share
Price / Book0.87

Profitability

EPS (Most Recent Fiscal Year)($1.78)
Net Income$22.97 million
Net MarginsN/A
Return on Equity-62.53%
Return on Assets-38.56%

Miscellaneous

Employees22
Outstanding Shares9,550,000

How to Become a New Pot Stock Millionaire

Caladrius Biosciences (NASDAQ:CLBS) Frequently Asked Questions

What is Caladrius Biosciences' stock symbol?

Caladrius Biosciences trades on the NASDAQ under the ticker symbol "CLBS."

How were Caladrius Biosciences' earnings last quarter?

Caladrius Biosciences (NASDAQ:CLBS) posted its earnings results on Thursday, March, 22nd. The biotechnology company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.70) by $0.30. View Caladrius Biosciences' Earnings History.

When is Caladrius Biosciences' next earnings date?

Caladrius Biosciences is scheduled to release their next quarterly earnings announcement on Wednesday, May, 16th 2018. View Earnings Estimates for Caladrius Biosciences.

What price target have analysts set for CLBS?

2 brokers have issued twelve-month price targets for Caladrius Biosciences' stock. Their predictions range from $7.00 to $12.00. On average, they expect Caladrius Biosciences' share price to reach $9.50 in the next twelve months. View Analyst Ratings for Caladrius Biosciences.

Who are some of Caladrius Biosciences' key competitors?

Who are Caladrius Biosciences' key executives?

Caladrius Biosciences' management team includes the folowing people:
  • David J. Mazzo Ph.D., Chief Executive Officer, Independent Director (Age 59)
  • Joseph Talamo, Chief Financial Officer, Senior Vice President (Age 47)
  • Douglas W. Losordo M.D., Chief Medical Officer (Age 58)
  • Gregory B. Brown M.D., Director (Age 64)
  • Richard J. Berman J.D., Independent Director (Age 75)
  • Drew Bernstein CPA., , Independent Director (Age 59)
  • Martyn D. Greenacre, Independent Director (Age 75)
  • Steven Mark Klosk, Independent Director (Age 60)

Has Caladrius Biosciences been receiving favorable news coverage?

News stories about CLBS stock have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a media sentiment score of 0.14 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 46.12 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Caladrius Biosciences?

Shares of CLBS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Caladrius Biosciences' stock price today?

One share of CLBS stock can currently be purchased for approximately $4.63.

How big of a company is Caladrius Biosciences?

Caladrius Biosciences has a market capitalization of $43.18 million and generates $35.28 million in revenue each year. The biotechnology company earns $22.97 million in net income (profit) each year or ($1.78) on an earnings per share basis. Caladrius Biosciences employs 22 workers across the globe.

How can I contact Caladrius Biosciences?

Caladrius Biosciences' mailing address is 106 ALLEN ROAD FOURTH FLOOR, BASKING RIDGE NJ, 07920. The biotechnology company can be reached via phone at 908-842-0100 or via email at [email protected]


MarketBeat Community Rating for Caladrius Biosciences (CLBS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  209 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Caladrius Biosciences and other stocks. Vote "Outperform" if you believe CLBS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLBS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Caladrius Biosciences (NASDAQ:CLBS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Caladrius Biosciences in the last 12 months. Their average twelve-month price target is $9.50, suggesting that the stock has a possible upside of 105.18%. The high price target for CLBS is $12.00 and the low price target for CLBS is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $9.50$12.00$7.00$6.75
Price Target Upside: 105.18% upside108.70% upside72.41% upside72.19% upside

Caladrius Biosciences (NASDAQ:CLBS) Consensus Price Target History

Price Target History for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ:CLBS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/23/2018Chardan CapitalBoost Price TargetBuy -> Buy$6.50 -> $7.00HighView Rating Details
3/14/2018HC WainwrightReiterated RatingBuy$12.00LowView Rating Details
5/14/2016Maxim GroupReiterated RatingHoldN/AView Rating Details
4/30/2016Rodman & RenshawUpgradeBuyN/AView Rating Details
(Data available from 4/21/2016 forward)

Earnings

Caladrius Biosciences (NASDAQ:CLBS) Earnings History and Estimates Chart

Earnings by Quarter for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ:CLBS) Earnings Estimates

Current Year EPS Consensus Estimate: $-3.05 EPS
Next Year EPS Consensus Estimate: $-2.1 EPS

Caladrius Biosciences (NASDAQ CLBS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/16/2018($0.80)N/AView Earnings Details
3/22/2018n/a($0.70)($0.40)ViewListenView Earnings Details
11/9/2017Q3 2017($0.79)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.96)($0.88)ViewN/AView Earnings Details
5/18/2017Q1 2017($0.72)($1.1160)$9.50 million$7.92 millionViewN/AView Earnings Details
3/17/2017Q4 2016($0.80)($0.73)$6.30 million$10.18 millionViewN/AView Earnings Details
11/7/2016Q3($1.55)($1.09)$7.70 million$9.32 millionViewListenView Earnings Details
8/9/2016Q216($1.75)($1.33)$7.53 million$8.30 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.80)($2.10)$10.40 million$7.49 millionViewN/AView Earnings Details
3/15/2016Q4($0.28)($0.59)$7.67 million$7.60 millionViewListenView Earnings Details
11/5/2015Q3 2015($0.30)($0.21)$6.00 million$5.89 millionViewN/AView Earnings Details
8/6/2015Q215($0.32)($0.31)$5.20 million$5.87 millionViewN/AView Earnings Details
5/5/2015Q1 2015($4.60)($4.80)$4.50 million$3.17 millionViewN/AView Earnings Details
3/2/2015Q4 2014($4.90)($4.40)$5.20 million$5.28 millionViewN/AView Earnings Details
10/30/2014Q3 2014($0.41)($0.44)$4.00 million$4.12 millionViewN/AView Earnings Details
8/7/2014Q2 2014($0.28)($0.38)$4.70 million$4.49 millionViewN/AView Earnings Details
5/8/2014Q1 2014($3.30)$4.06 millionViewN/AView Earnings Details
3/13/2014Q4 2013($4.70)$4.08 millionViewN/AView Earnings Details
11/7/2013Q3 2013($4.50)$3.71 millionViewN/AView Earnings Details
8/8/2013Q2 2013($4.60)$4.36 millionViewN/AView Earnings Details
5/9/2013Q1 2013($5.00)($5.00)$4.20 million$2.52 millionViewN/AView Earnings Details
11/14/2012Q312($0.05)($0.06)$3.50 million$4.40 millionViewN/AView Earnings Details
8/14/2012Q2 2012($5.40)ViewN/AView Earnings Details
5/11/2012Q1 2012($6.80)ViewN/AView Earnings Details
3/20/2012Q4 2011($7.00)$1.20ViewN/AView Earnings Details
11/11/2011Q3 2011($12.00)($8.00)ViewN/AView Earnings Details
8/15/2011Q2 2011($9.00)($13.40)ViewN/AView Earnings Details
11/12/2010Q3 2010($10.00)($12.60)ViewN/AView Earnings Details
8/16/2010Q2 2010($7.00)($11.10)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Caladrius Biosciences (NASDAQ:CLBS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Caladrius Biosciences (NASDAQ CLBS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.10%
Institutional Ownership Percentage: 5.71%
Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)
Insider Trading History for Caladrius Biosciences (NASDAQ:CLBS)

Caladrius Biosciences (NASDAQ CLBS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/7/2017Eric WeiDirectorSell6,575$4.77$31,362.75View SEC Filing  
2/6/2017Eric WeiDirectorSell8,425$4.61$38,839.25View SEC Filing  
7/1/2016Eric WeiDirectorSell87,500$0.60$52,500.00View SEC Filing  
6/24/2016Eric WeiDirectorSell22,698$0.55$12,483.90View SEC Filing  
8/17/2015David J MazzoCEOBuy20,000$1.40$28,000.00View SEC Filing  
8/11/2015Robert S VatersCFOBuy81,000$1.24$100,440.00View SEC Filing  
12/9/2014Steven S MyersDirectorBuy20,000$3.56$71,200.00View SEC Filing  
12/8/2014Rimasia Capital Partners ManagDirectorSell16,060$3.75$60,225.00View SEC Filing  
12/3/2014Rimasia Capital Partners ManagDirectorSell12,000$4.01$48,120.00View SEC Filing  
12/1/2014Steven S MyersDirectorBuy10,000$3.92$39,200.00View SEC Filing  
11/25/2014Steven M KloskDirectorBuy10,000$3.99$39,900.00View SEC Filing  
11/24/2014Andrew L PecoraInsiderBuy12,500$4.01$50,125.00View SEC Filing  
11/24/2014Steven S MyersDirectorBuy19,800$3.94$78,012.00View SEC Filing  
12/12/2013Richard BermanDirectorSell12,218$5.99$73,185.82View SEC Filing  
12/9/2013Rimasia Capital Partners Managmajor shareholderSell12,530$6.37$79,816.10View SEC Filing  
12/28/2012Richard J BermanDirectorSell149,306$0.59$88,090.54View SEC Filing  
9/18/2012Richard J BermanDirectorSell36,000$0.69$24,840.00View SEC Filing  
9/17/2012Rimasia Capital Partners ManagMajor ShareholderSell30,000$0.71$21,300.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Caladrius Biosciences (NASDAQ CLBS) News Headlines

Source:
DateHeadline
Wired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart FailureWired News - Mesoblast Announced Updated Data from Phase-3 and Phase-2b Clinical Trials of MPC-150-IM in Patients with Chronic Heart Failure
finance.yahoo.com - April 20 at 8:24 AM
Fresenius Medical Care (FMS) & Caladrius Biosciences (CLBS) Financial SurveyFresenius Medical Care (FMS) & Caladrius Biosciences (CLBS) Financial Survey
www.americanbankingnews.com - April 16 at 7:17 AM
Comparing Tivity Health (TVTY) & Caladrius Biosciences (CLBS)Comparing Tivity Health (TVTY) & Caladrius Biosciences (CLBS)
www.americanbankingnews.com - April 15 at 9:27 AM
Caladrius Biosciences (CLBS) vs. Fresenius Medical Care (FMS) Critical SurveyCaladrius Biosciences (CLBS) vs. Fresenius Medical Care (FMS) Critical Survey
www.americanbankingnews.com - April 13 at 11:55 PM
Caladrius Bios CLBS12 nabs accelerated review status in Japan for critical limb ischemiaCaladrius Bio's CLBS12 nabs accelerated review status in Japan for critical limb ischemia
seekingalpha.com - April 10 at 5:22 PM
Caladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb IschemiaCaladrius Biosciences Receives SAKIGAKE Expedited Review Designation in Japan for CLBS12 for Treating Critical Limb Ischemia
finance.yahoo.com - April 10 at 8:20 AM
Caladrius Biosciences to Participate at Upcoming April ConferencesCaladrius Biosciences to Participate at Upcoming April Conferences
finance.yahoo.com - April 9 at 5:25 PM
Caladrius Biosciences (CLBS) Rating Lowered to Sell at Zacks Investment ResearchCaladrius Biosciences (CLBS) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 6 at 8:10 PM
-$0.82 EPS Expected for Caladrius Biosciences (CLBS) This Quarter-$0.82 EPS Expected for Caladrius Biosciences (CLBS) This Quarter
www.americanbankingnews.com - April 5 at 1:12 PM
Caladrius Biosciences to Present at The MicroCap ConferenceCaladrius Biosciences to Present at The MicroCap Conference
finance.yahoo.com - April 3 at 8:13 AM
Head-To-Head Comparison: Caladrius Biosciences (CLBS) vs. American Renal Associates (ARA)Head-To-Head Comparison: Caladrius Biosciences (CLBS) vs. American Renal Associates (ARA)
www.americanbankingnews.com - April 2 at 7:52 AM
Contrasting Caladrius Biosciences (CLBS) & Catasys (CATS)Contrasting Caladrius Biosciences (CLBS) & Catasys (CATS)
www.americanbankingnews.com - April 1 at 9:22 PM
Catasys (CATS) & Caladrius Biosciences (CLBS) Critical ReviewCatasys (CATS) & Caladrius Biosciences (CLBS) Critical Review
www.americanbankingnews.com - April 1 at 9:20 PM
Caladrius Biosciences (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaCaladrius Biosciences' (CLBS) CEO David Mazzo on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 24 at 8:29 AM
Chardan Capital Increases Caladrius Biosciences (CLBS) Price Target to $7.00Chardan Capital Increases Caladrius Biosciences (CLBS) Price Target to $7.00
www.americanbankingnews.com - March 23 at 4:00 PM
Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results - GlobeNewswire (press release)Caladrius Biosciences Reports 2017 Fourth Quarter and Year End Financial Results - GlobeNewswire (press release)
globenewswire.com - March 23 at 8:21 AM
Caladrius Biosciences (CLBS) Releases Quarterly  Earnings Results, Beats Expectations By $0.29 EPSCaladrius Biosciences (CLBS) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS
www.americanbankingnews.com - March 23 at 7:52 AM
 Analysts Expect Caladrius Biosciences Inc (CLBS) Will Post Earnings of -$0.83 Per Share Analysts Expect Caladrius Biosciences Inc (CLBS) Will Post Earnings of -$0.83 Per Share
www.americanbankingnews.com - March 19 at 1:54 PM
Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday ... - NasdaqCaladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday ... - Nasdaq
www.nasdaq.com - March 17 at 9:22 AM
Caladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern TimeCaladrius Biosciences to Host Fourth Quarter and Year End 2017 Financial Results Conference Call on Thursday, March 22, 2018 at 4:30 p.m. Eastern Time
finance.yahoo.com - March 15 at 9:38 AM
HC Wainwright Reiterates "Buy" Rating for Caladrius Biosciences (CLBS)HC Wainwright Reiterates "Buy" Rating for Caladrius Biosciences (CLBS)
www.americanbankingnews.com - March 14 at 3:14 PM
Caladrius Biosciences (CLBS) Reports Dosing of 1st Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in JapanCaladrius Biosciences (CLBS) Reports Dosing of 1st Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan
www.streetinsider.com - March 13 at 9:53 AM
Caladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in JapanCaladrius Biosciences Doses First Patient with CLBS12 in Phase 2 Critical Limb Ischemia Trial in Japan
finance.yahoo.com - March 13 at 9:53 AM
Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - GlobeNewswire (press release)Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium - GlobeNewswire (press release)
globenewswire.com - March 9 at 5:38 PM
Caladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering SymposiumCaladrius Biosciences to Present at the B. Riley FBR Inaugural China Healthcare Investing & Partnering Symposium
finance.yahoo.com - March 8 at 5:25 PM
Caladrius Biosciences (CLBS) Announces Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes - StreetInsider.comCaladrius Biosciences (CLBS) Announces Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes - StreetInsider.com
www.streetinsider.com - March 8 at 9:32 AM
Caladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 DiabetesCaladrius Biosciences Reports Interim Analysis for Phase 2 T-Rex Trial of CLBS03 for Type 1 Diabetes
finance.yahoo.com - March 8 at 9:32 AM
Caladrius Biosciences (CLBS) Set to Announce Quarterly Earnings on ThursdayCaladrius Biosciences (CLBS) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 8 at 1:11 AM
Caladrius Biosciences (CLBS) Given a $7.00 Price Target by HC Wainwright AnalystsCaladrius Biosciences (CLBS) Given a $7.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 6 at 8:04 PM
Here’s Why Caladrius Biosciences Inc (CLBS) Shares Are Skyrocketing TodayHere’s Why Caladrius Biosciences Inc (CLBS) Shares Are Skyrocketing Today
finance.yahoo.com - March 6 at 5:16 PM
-$0.83 Earnings Per Share Expected for Caladrius Biosciences Inc (CLBS) This Quarter-$0.83 Earnings Per Share Expected for Caladrius Biosciences Inc (CLBS) This Quarter
www.americanbankingnews.com - March 2 at 12:08 PM
Caladrius Biosciences (CLBS) Presents At BIO CEO & Investor Conference - SlideshowCaladrius Biosciences (CLBS) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:28 PM
Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)Caladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference - GlobeNewswire (press release)
globenewswire.com - February 8 at 7:01 AM
Caladrius Biosciences to Present at the 2018 BIO CEO & Investor ConferenceCaladrius Biosciences to Present at the 2018 BIO CEO & Investor Conference
finance.yahoo.com - February 8 at 7:01 AM
Caladrius Biosciences (CLBS) PT Set at $7.00 by HC WainwrightCaladrius Biosciences (CLBS) PT Set at $7.00 by HC Wainwright
www.americanbankingnews.com - January 20 at 1:58 PM
Zacks Investment Research Lowers Caladrius Biosciences (CLBS) to SellZacks Investment Research Lowers Caladrius Biosciences (CLBS) to Sell
www.americanbankingnews.com - January 10 at 7:46 PM
Caladrius Biosciences (CLBS) & Its Competitors Head-To-Head ReviewCaladrius Biosciences (CLBS) & Its Competitors Head-To-Head Review
www.americanbankingnews.com - January 1 at 3:28 AM
Reviewing Caladrius Biosciences (CLBS) and Its PeersReviewing Caladrius Biosciences (CLBS) and Its Peers
www.americanbankingnews.com - December 26 at 11:54 PM
Caladrius Biosciences (CLBS) and Its Competitors Financial AnalysisCaladrius Biosciences (CLBS) and Its Competitors Financial Analysis
www.americanbankingnews.com - December 19 at 5:26 AM
Financial Analysis: Caladrius Biosciences (CLBS) vs. Its PeersFinancial Analysis: Caladrius Biosciences (CLBS) vs. Its Peers
www.americanbankingnews.com - December 17 at 3:12 AM
Contrasting Caladrius Biosciences (CLBS) and The CompetitionContrasting Caladrius Biosciences (CLBS) and The Competition
www.americanbankingnews.com - December 13 at 7:24 PM
Caladrius Biosciences (CLBS) versus Its Peers Head to Head ReviewCaladrius Biosciences (CLBS) versus Its Peers Head to Head Review
www.americanbankingnews.com - December 12 at 9:34 PM
ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017ETFs with exposure to Caladrius Biosciences, Inc. : December 8, 2017
finance.yahoo.com - December 8 at 5:14 PM
Caladrius Biosciences (CLBS) vs. Its Competitors Financial ReviewCaladrius Biosciences (CLBS) vs. Its Competitors Financial Review
www.americanbankingnews.com - December 4 at 1:34 AM
Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event - GlobeNewswire (press release)Caladrius Biosciences to Present at the 10th Annual LD Micro Main Event - GlobeNewswire (press release)
globenewswire.com - December 3 at 5:20 PM
Zacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to HoldZacks Investment Research Lowers Caladrius Biosciences, Inc. (CLBS) to Hold
www.americanbankingnews.com - November 16 at 5:34 PM
Caladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment ResearchCaladrius Biosciences, Inc. (CLBS) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - November 15 at 9:00 PM
Caladrius Biosciences, Inc. (CLBS) Releases  Earnings Results, Beats Expectations By $0.41 EPSCaladrius Biosciences, Inc. (CLBS) Releases Earnings Results, Beats Expectations By $0.41 EPS
www.americanbankingnews.com - November 10 at 12:51 PM
Caladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC WainwrightCaladrius Biosciences, Inc. (CLBS) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - November 10 at 10:24 AM
Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)Caladrius Biosciences Reports 2017 Third Quarter Results - GlobeNewswire (press release)
www.globenewswire.com - November 10 at 9:52 AM

SEC Filings

Caladrius Biosciences (NASDAQ:CLBS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Caladrius Biosciences (NASDAQ:CLBS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Caladrius Biosciences (NASDAQ CLBS) Stock Chart for Saturday, April, 21, 2018

Loading chart…

This page was last updated on 4/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.